ASR Vermogensbeheer N.V. Takes Position in DaVita Inc. (NYSE:DVA)

Key Points

• ASR Vermogensbeheer N.V. acquired a new stake in DaVita Inc. worth approximately $2.53 million, purchasing 16,564 shares in the company's stock in the first quarter.
• Multiple institutional investors have increased their holdings in DaVita, with a collective ownership of over 90% of the company's stock.
• Analysts have set new price targets for DaVita, with recent ratings showing a consensus average target price of $170.75, reflecting ongoing cautious sentiments in the market.

ASR Vermogensbeheer N.V. acquired a new stake in DaVita Inc. (NYSE:DVA - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,564 shares of the company's stock, valued at approximately $2,534,000.

Other large investors have also bought and sold shares of the company. Wellington Management Group LLP lifted its holdings in DaVita by 9.1% in the 4th quarter. Wellington Management Group LLP now owns 2,711 shares of the company's stock valued at $405,000 after acquiring an additional 227 shares during the last quarter. Fifth Third Bancorp lifted its stake in DaVita by 5.0% during the first quarter. Fifth Third Bancorp now owns 4,274 shares of the company's stock valued at $654,000 after purchasing an additional 204 shares during the last quarter. Concurrent Investment Advisors LLC bought a new stake in DaVita during the first quarter worth approximately $223,000. Wealth Enhancement Advisory Services LLC grew its position in DaVita by 22.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 4,351 shares of the company's stock worth $666,000 after buying an additional 800 shares during the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in shares of DaVita by 7.9% in the first quarter. Envestnet Asset Management Inc. now owns 55,255 shares of the company's stock valued at $8,452,000 after buying an additional 4,048 shares in the last quarter. Institutional investors own 90.12% of the company's stock.

Analysts Set New Price Targets

DVA has been the subject of several research reports. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Truist Financial decreased their price target on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a research report on Monday, May 19th. Finally, Barclays cut their price objective on DaVita from $169.00 to $160.00 and set an "equal weight" rating on the stock in a report on Thursday. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $170.75.

Insider Activity

In related news, insider James O. Hearty sold 2,351 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total transaction of $352,650.00. Following the transaction, the insider directly owned 26,038 shares of the company's stock, valued at approximately $3,905,700. The trade was a 8.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 2.00% of the stock is owned by company insiders.

DaVita Price Performance

DVA opened at $127.61 on Friday. The firm has a market capitalization of $9.12 billion, a P/E ratio of 12.55, a PEG ratio of 0.88 and a beta of 1.09. The stock has a fifty day moving average of $140.15 and a 200-day moving average of $147.07. The company has a quick ratio of 1.20, a current ratio of 1.39 and a debt-to-equity ratio of 23.18. DaVita Inc. has a 12-month low of $126.07 and a 12-month high of $179.60.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $2.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.70 by $0.25. DaVita had a return on equity of 369.39% and a net margin of 6.35%. The firm had revenue of $3.38 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same period in the prior year, the business earned $2.00 EPS. The business's revenue for the quarter was up 6.1% on a year-over-year basis. Equities analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.